All In Biotech

Drug Trial Radar · NCT07919015

Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

A Prospective, Multicenter, Observational Real-world Study of Nerandomilast Efficacy and Safety in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Feb 1, 2026

Primary completion

Jun 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Avraham UntermanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Rambam Health Care Campus; Barzilai University Medical Center; The Chaim Sheba Medical Center
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Nerandomilast is an oral medicine that slows down the loss of functional residual capacity (FVC) in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It was tested in two large clinical trials in which participants were carefully selected. In everyday practice, patients are often older, have more other illnesses, or take additional medicines, and it is not known whether the benefits seen in the trials also occur outside them. The Real-world Study of Nerandomilast (ReaSoN-IPF/PPF) follows people with IPF or PPF who begin nerandomilast as part of their usual medical care at several medical centers in Israel. The study does not assign any treatment; the treating physician makes every decision about therapy. The main goal is to find out whether lung function declines more slowly once nerandomilast is started. Because patients have breathing tests before they begin the medicine as well as during treatment, each patient is compared with themselves: the rate at which their FVC was declining beforehand is compared with the rate following treatment. The study also asks how patients feel, using a questionnaire called the K-BILD, and records side effects, hospital admissions, disease exacerbations, and whether patients stop the medicine. Participants attend their normal clinic visits. They complete the questionnaire before treatment starts and again at 6 to 12 months, and their routine lung function results are collected. No extra tests or visits are required beyond the questionnaire.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Progressive Pulmonary Fibrosis

Interventions

  • NerandomilastDrug

    Either Nerandomilast 9mg twice a day or 18mg twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Through study completion, an average of 9 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Barzilai Medical Center, Ben-Gurion University of the Negev

    Ashkelon, Israel · Recruiting

  • Rambam Health Care Campus, Technion - Israel Institute of Technology

    Haifa, Israel · Recruiting

  • Sheba Medical Center, Tel-HaShomer, Tel-Aviv University

    Ramat Gan, Israel · Recruiting

  • Tel-Aviv Sourasky University Medical Center, Tel-Aviv University

    Tel Aviv, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.